Pacific Biosciences of California, Inc. (PACB): Price and Financial Metrics

Pacific Biosciences of California, Inc. (PACB): $32.00

-0.15 (-0.47%)

POWR Rating

Component Grades














  • Quality is the dimension where PACB ranks best; there it ranks ahead of 67.94% of US stocks.
  • The strongest trend for PACB is in Growth, which has been heading down over the past 31 weeks.
  • PACB's current lowest rank is in the Sentiment metric (where it is better than 10.81% of US stocks).

PACB Stock Summary

  • PACB's price/sales ratio is 67.73; that's higher than the P/S ratio of 95.68% of US stocks.
  • With a year-over-year growth in debt of 1,987.38%, Pacific Biosciences Of California Inc's debt growth rate surpasses 99.07% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PACB comes in at -18.42% -- higher than that of just 14.13% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Pacific Biosciences Of California Inc, a group of peers worth examining would be PLAN, DRNA, XNCR, SMAR, and STXS.
  • Visit PACB's SEC page to see the company's official filings. To visit the company's web site, go to

PACB Valuation Summary

  • PACB's EV/EBIT ratio is -104.8; this is 492.51% lower than that of the median Healthcare stock.
  • Over the past 131 months, PACB's price/sales ratio has gone down 564.2.
  • PACB's price/sales ratio has moved down 564.2 over the prior 131 months.

Below are key valuation metrics over time for PACB.

Stock Date P/S P/B P/E EV/EBIT
PACB 2020-06-09 6.9 10.3 -11.8 -11.8
PACB 2019-07-29 10.5 8.4 -7.3 -7.8
PACB 2017-10-17 5.4 4.5 -6.1 -6.0
PACB 2013-08-15 11.7 2.4 -2.8 -2.5
PACB 2012-11-19 2.2 0.6 -0.7 -0.4
PACB 2012-05-08 3.2 0.8 -1.4 -0.8

PACB Growth Metrics

  • Its 5 year net income to common stockholders growth rate is now at -6.67%.
  • The year over year cash and equivalents growth rate now stands at 1255.22%.
  • The 4 year net income to common stockholders growth rate now stands at -70.2%.
PACB's revenue has moved up $18,887,000 over the prior 67 months.

The table below shows PACB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 92.292 -78.964 -59.294
2020-12-31 78.893 19.503 29.403
2020-09-30 79.687 15.586 -45.623
2020-06-30 82.52 16.134 -51.038
2020-03-31 90.064 22.364 -52.548
2019-12-31 90.891 -78.312 -84.134

PACB Price Target

For more insight on analysts targets of PACB, see our PACB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $47.25 Average Broker Recommendation 1.7 (Moderate Buy)

PACB Stock Price Chart Interactive Chart >

Price chart for PACB

PACB Price/Volume Stats

Current price $32.00 52-week high $53.69
Prev. close $32.15 52-week low $3.74
Day low $31.56 Volume 1,298,568
Day high $32.31 Avg. volume 3,558,902
50-day MA $29.82 Dividend yield N/A
200-day MA $28.02 Market Cap 6.35B

Pacific Biosciences of California, Inc. (PACB) Company Bio

Pacific Biosciences of California, Inc. designs, develops, manufactures, and markets an integrated platform for genetic analysis. The company was formerly known as Nanofluidics, Inc. The company was founded in 2000 and is based in Menlo Park, California.

PACB Latest News Stream

Event/Time News Detail
Loading, please wait...

PACB Latest Social Stream

Loading social stream, please wait...

View Full PACB Social Stream

Latest PACB News From Around the Web

Below are the latest news stories about Pacific Biosciences Of California Inc that investors may wish to consider to help them evaluate PACB as an investment opportunity.

Pacific Biosciences Grants Equity Incentive Award to New Employee

MENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (“Pacific Biosciences” or the “Company”), a leading provider of high-quality sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted restricted stock units (“RSUs”) covering 29,500 shares of Pacific Biosciences common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the “2020

Yahoo | July 28, 2021

Earnings Preview: Pacific Biosciences of California (PACB) Q2 Earnings Expected to Decline

Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 27, 2021

PacBio (PACB) Enhances Sequencing Platform Via Latest Buyout

PacBio's (PACB) latest acquisition is expected to deliver the most advanced blend of sequencing solutions to transform the genomics landscape.

Yahoo | July 23, 2021

Here is What Hedge Funds Think About Pacific Biosciences of California, Inc. (PACB)

Is Pacific Biosciences of California, Inc. (NASDAQ:PACB) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial […]

Yahoo | July 20, 2021

Pacific Biosciences To Buy DNA Sequencing Firm For Up To $800M, Announces $300M Capital Raise For Deal Funding

View more earnings on PACBSee more from BenzingaClick here for options trades from BenzingaSupply Chain Issues Hit Neogen's Q4 Margins, EarningsAldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate© 2021 Benzinga does not provide investment advice. All rights reserved.

Yahoo | July 20, 2021

Read More 'PACB' Stories Here

PACB Price Returns

1-mo -4.42%
3-mo 25.69%
6-mo -8.10%
1-year 757.91%
3-year 739.90%
5-year 312.90%
YTD 23.36%
2020 404.67%
2019 -30.54%
2018 180.30%
2017 -30.53%
2016 -71.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8799 seconds.